Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Next Previous
Drug Profile

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Alternative Names: ALT 803; ANKTIVA; IL-15N72D/IL-15Ra-Fc - Altor BioScience Corporation; IL-15N72D:IL-15RαSu/Fc fusion protein complex; IL-15sa - Altor BioScience Corporation; Interleukin 15 superagonist - Altor BioScience Corporation; N-803; Nogapendekin alfa inbakicept - ImmunityBio; Nogapendekin alfa inbakicept-pmln - Altor BioScience Corporation; Superagonist Interleukin-15:Interleukin-15 receptor alphaSu/Fc Fusion complex - Altor BioScience Corporation; VesAnktiva™

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation
  • Developer Altor BioScience Corporation; ImmunityBio; National Cancer Institute (USA); Serum Life Science Europe
  • Class Antineoplastics; Antiretrovirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Registered Lymphopenia; Non-small cell lung cancer
  • Phase III Colorectal cancer
  • Phase II Acute myeloid leukaemia; Cervical cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Post acute COVID 19 syndrome; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II Endometrial cancer; Multiple myeloma; Prostate cancer; Triple negative breast cancer
  • Phase I Cancer
  • No development reported COVID 2019 infections; HIV-1 infections

Most Recent Events

  • 17 Mar 2026 ImmunityBio plans a phase II trial of N-803 for Non Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) (IV) in April 2026 (NCT07477366)
  • 09 Mar 2026 ImmunityBio announces intention to submit biologics license application (BLA) to the US FDA for Bladder cancer by year end 2026
  • 09 Mar 2026 ImmunityBio resubmits supplemental BLA to the US FDA for Nogapendekin alpfa inbakicept for Bladder cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top